A type of drug known as a PARP inhibitor, already used to treat breast and ovarian cancer, may be useful in treating children with high-risk neuroblastoma – a common childhood tumour with a low survival rate.

New research has helped create a mouse model to help study a devastating childhood cancer and understand how it spreads.

A new study has shown the power of genetic testing to pick out the best drugs for children with cancer to extend and improve their lives – signalling a new era of precision medicine for young patients.